Halden Bio — device programme 04
Tempo
The weekly shot was never the point. The blood level was.
A GLP-1 agonist works on a concentration, not on an event. We kept shipping the event and hoping the concentration followed.
Scroll ↓
01 — The sawtooth
A pulse, not a level
One injection a week produces one shape: a climb of about thirty hours, then a decay that runs for the rest of the week.
The dose is chosen for the trough, so the peak is always larger than the body needs. Nausea lives on the peak.
02 — Day six
Under the floor
Below the therapeutic floor the drug is still present and still costing the patient money, but it is no longer doing the work.
Appetite returns before the next dose does. Patients read that as failure and stop. Half of them stop inside a year.
03 — The patch
28 days on the skin
Tempo is a 62 mm adhesive patch. A dry reservoir holds 28 days of agonist. An electro-osmotic pump moves 0.6 µL at a time through a coated microneedle array that stops in the dermis.
No sharps, no cold chain, no calendar. The patient changes it on the same weekday each month.
04 — The loop
It titrates itself
The same patch carries an interstitial glucose sensor and a skin temperature probe. The on-patch model reads both, compares them with the last 72 hours, and sets the next stroke.
Escalation stops being a clinic visit. The curve walks itself up over six weeks and holds where the patient tolerates it.
05 — Flat
The same drug, spread thin
Weekly milligrams are unchanged. Only the shape changes. The peak disappears because it was never therapy, and the trough disappears because it was never intended.
What is left is a band the patient sits inside all month.
06 — What flat buys
Result
Simulated 12-month cohort, 1,400 virtual patients, matched weekly milligrams.
End